Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients. Our small molecule, first-in-class anti-metabolite approach (PBT) should be useful against many hyper-proliferative disease states, yet due to the strong animal efficacy data in hand; it is the strategy of the company to pursue its use for Head and Neck/Squamous Cell Carcinoma (HNSCC) as its first cancer indication. Animex Therapeutics’ recent experiments have demonstrated that PBT has a unique mechanism of action that, when viewed in conjunction with durable cures observed following treatment in animals; give it a clear competitive market advantage.